Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Business In Brief

Executive Summary

Graceway licenses derm compounds from Pfizer: In Pfizer's first out-licensing transaction since announcing its merger with Wyeth in January, the pharma is selling worldwide commercial rights and related intellectual property to three investigational dermatology candidates to Graceway Pharmaceuticals. Financial terms were not disclosed. Pfizer said the deal is part of its "plan to out-license R&D programs that are no longer core to its strategy." Privately held Graceway gains two Phase II programs for treatment of oily skin and acne - an SCD1 inhibitor and an ACAT inhibitor - along with a preclinical ALK-5 inhibitor for reduction of surgical and traumatic scars. In addition to dermatology, Graceway also markets drugs in the respiratory and women's health areas

You may also be interested in...

Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility

King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.

Acurox Panel Review Complicated By FDA's Uncertainty Over How Much Evidence Is Needed To Prove Abuse Deterrence

FDA is not convinced that additives meant to make the immediate-release oxycodone formulation difficult to ingest, snort or inject will have their intended deterrent effect.

Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon

Watson's own citizen petitions blocking generics won't be an obstacle, company says.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts